Azacitidine demethylates, causes gain in CTCF occupancy, and increases KLF6 gene expression. (A) Integrative Genomics Viewer tracks visualize a CTCF peak, the green box represents a differentially bound peak, and the pink boxes a detected CpG by the EPIC array, overlapping with the DBC peak. (B) Expression levels of KLF6 gene (*FDR <0.05, fold change >1.5). (C) Methylation of the 2 CpGs shown in panel A as measured by β-values (*FDR <0.1). (D) Venn diagram showing the overlap CTCF-binding sites gained with azacitidine treatment (red circle) and CTCF-binding sites bound in NBM. There are significant number of gained CTCFs in AML^aza that overlap with NBM (Z-test, P < .001).